Recruiting

Observational Study

Sponsor:

The University of Texas Health Science Center at San Antonio

Code:

NCT07780513

Conditions

Insulin Stimulated

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Insulin 80mU/m2*min

Study Details

Brief summary:

In this study, the investigators will use euglycemic/hyperinsulinemic clamps, longitudinal skeletal muscle biopsies, and single nucleus ribonucleic acid sequencing (RNA-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC- seq) to reveal cell type-specific molecular response quantitative trait loci (rQTLs) acutely regulated by insulin signaling and glucose uptake.

Conditions

Insulin Stimulated

Study ID

NCT07780513

Start date

Aug 31, 2026

Status verified date

Aug, 2026

Completion date

Jul 31, 2031

Anticipated

Primary completion date

Jul 31, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Males and Females Age 18-75
  • Body Mass Index (BMI) > 18
  • Normal glucose tolerance as defined by:

Fasting blood sugar < 100 mg/dL 2-hour Oral Glucose Tolerance Test (OGTT) < 140mg/dL Stable weight over the past 3 months defined as >±5% change in body weight

  • Hemoglobin A1c < 5.7
  • Creatinine < 2
  • Aspartate aminotransferase/Alanine transaminase (AST/ALT) < 75
  • Blood sodium 135 to 145 mEq/L
  • Blood potassium 3.6 to 5.2 mmol/L\[MH1.1\]

Exclusion Criteria:

  • Urine albumin excretion>300mg/day
  • Partial thromboplastin time (PTT) >35International normalized ratio (INR) > 1.2
  • No oral corticosteroids for 1 month
  • No Sodium-glucose co-transporter 2 (SGLT2) inhibitor for 3 months
  • No glucagon-like peptide-1 (GLP-1) receptor agonist for 6 months
  • Any anti-platelet or anti-coagulation medication other than as needed for Pain Management
  • No alcohol 4 days before the insulin clamp and biopsy procedure
  • No acute structural knee injuries
  • No Rheumatologic muscular or nervous system disease
  • Pregnancy, Intentions to become pregnant, or Breastfeeding
  • Blood Pressure >170/110
  • Temperature > 100F
  • Triglycerides > 400 by lipid panel
  • Hemoglobin <10g/dL
  • 1+ or greater Blood on Urinalysis
  • 2+ or greater Protein on Urinalysis
  • Electrocardiogram (EKG) abnormalities, including but not limited to ST elevations, T wave abnormalities, evidence of recent prior infarct

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Insulin stimulated

80mU/m2\*min euglycemic/hyperinsulinemic clamp

Interventions

Insulin 80mU/m2*min

80mU/m2\*min euglycemic-hyperinsulinemic clamp

Primary outcome measure

  • Cell type specific quantitative trait loci in skeletal muscle [ Time Frame: Before and after insulin clamp (Baseline to approximately 6 hours) ]

Central Contacts and Locations

Central contacts

Luke Norton, Ph.D

210-567-0739nortonl@uthscsa.edu

Locations

Texas Diabetes Institute - University Health System, San Antonio, Texas 78207

Recruiting

San Antonio, Texas, United States, 78229

Contacts

Luke Norton, Ph.D

210-567-0739nortonl@uthscsa.edu

nortonl@uthscsa.edu

Principal Investigator:

Luke Norton, Ph.D

More Information

Sponsor

The University of Texas Health Science Center at San Antonio

Last update posted

Aug 24, 2026

Last verified

Aug, 2026

Keywords

  • Insulin
  • Skeletal muscle
  • Quantitative trait loci (QTL)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio on 2026-08-24.